Medicinal marijuana use: experiences of people with multiple sclerosis.
OBJECTIVE
To describe medical marijuana use from the perspectives of patients with multiple sclerosis.


METHODS
A qualitative, descriptive design was used. Participants discussed their medicinal marijuana use in one-to-one, semistructured interviews.


METHODS
Interviews were conducted at a time and place convenient to participants.


METHODS
Six men and eight women with multiple sclerosis participated.


METHODS
Potential participants identified themselves to the researcher after receiving an invitation in a mailed survey. Eligibility was confirmed, and purposive sampling was used to recruit subjects. A range of issues emerged from the interviews. Interviews and data analysis continued until saturation occurred.


RESULTS
Descriptions fell into three broad areas: patterns of use, legal or social concerns, and perceived effects. Consumption patterns ranged from very infrequent to very regular and were influenced by symptoms, social factors, and supply. Legal concerns expressed by most respondents were negligible. Social concerns centred on to whom use was revealed. The perceived benefits of use were consistent with previous reports in the literature: reduction in pain, spasms, tremors, nausea, numbness, sleep problems, bladder and bowel problems, and fatigue and improved mood, ability to eat and drink, ability to write, and sexual functioning. Adverse effects included problems with cognition, balance, and fatigue and the feeling of being high. Although participants described risks associated with using marijuana, the benefits they derived made the risks acceptable.


CONCLUSIONS
Further research is needed to clarify the safety and efficacy of marijuana use by patients with multiple sclerosis. If evidence of benefit is seen, medicinal marijuana should be made available to patients who could benefit from it. Until then, discussing medicinal marijuana use with patients will be awkward for health professionals.
Page
Stacey A
SA
Office of Medical Bioethics, Faculty of Medicine, University of Calgary, Alberta. sapage@ucalgary.ca
Verhoef
Marja J
MJ
D000328:Adult; D002170:Canada; D002186:Cannabinoids / Q000627:therapeutic use*; D003430:Cross-Sectional Studies; D005260:Female; D006306:Health Surveys; D006801:Humans; D008297:Male; D008385:Marijuana Smoking / Q000009:adverse effects; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000150:complications / Q000188:drug therapy*; D018514:Plant Structures; D012307:Risk Factors; D016896:Treatment Outcome
D002186:Cannabinoids